Utama › Limfoma Bukan Hodgkin › Nebraska
Kajian klinikal Limfoma Bukan Hodgkin di Nebraska
15 kajian untuk Limfoma Bukan Hodgkin sedang mencari peserta di lokasi di Nebraska.
Bandar di Nebraska
Teks kajian rasmi (Bahasa Inggeris)
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT02693535A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- The University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07195916A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Local Institution - 0124, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06090539Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06528301A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Nebraska Medical Center (UNMC), Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07188558A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Nebraska Medical Center, Omaha
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545Halt Aging in Survivors of Blood Cancers
- University of Nebraska Medical Center, Omaha
Mengambil peserta
Umur 50 ke atas · Semua jantina · Dikemas kini 1 Jul 2026 · NCT07292272Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jun 2026 · NCT04068597CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Fred and Pamela Buffett Cancer Center, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT03328078Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- CHI Health Good Samaritan, Kearney
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- University Of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- University Of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06876662SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.